BKM120 Combined with Vemurafenib (PLX4032)
Phase 1/2Completed 0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
BRAF Mutant Metastatic Melanoma
Conditions
BRAF Mutant Metastatic Melanoma
Trial Timeline
Jun 9, 2012 → Mar 21, 2017
NCT ID
NCT01512251About BKM120 Combined with Vemurafenib (PLX4032)
BKM120 Combined with Vemurafenib (PLX4032) is a phase 1/2 stage product being developed by Novartis for BRAF Mutant Metastatic Melanoma. The current trial status is completed. This product is registered under clinical trial identifier NCT01512251. Target conditions include BRAF Mutant Metastatic Melanoma.
What happened to similar drugs?
0 of 2 similar drugs in BRAF Mutant Metastatic Melanoma were approved
Approved (0) Terminated (1) Active (1)
🔄Encorafenib + Binimetinib + Cetuximab + Irinotecan + Folinic Acid + 5-FluorouracilOno PharmaceuticalPhase 3
Hype Score Breakdown
Clinical
9
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01512251 | Phase 1/2 | Completed |
Competing Products
13 competing products in BRAF Mutant Metastatic Melanoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| PLX3397 + vemurafenib | Daiichi Sankyo | Phase 1 | 21 |
| TMZ + E7016 | Eisai | Phase 2 | 27 |
| Encorafenib + Binimetinib + Cetuximab + Irinotecan + Folinic Acid + 5-Fluorouracil | Ono Pharmaceutical | Phase 3 | 40 |
| encorafenib + Binimetinib + Cetuximab | Ono Pharmaceutical | Phase 2 | 35 |
| Encorafenib + Cetuximab + FOLFIRI | Merck | Phase 2 | 35 |
| Tafinlar/Mekinist | Novartis | Pre-clinical | 33 |
| Dabrafenib + LTT462 + Trametinib + LXH254 + TNO155 + Spartalizumab + Tislelizumab | Novartis | Phase 1 | 21 |
| Cobimetinib + Atezolizumab + Pembrolizumab | Roche | Phase 3 | 32 |
| LGX818 + MEK162 + LEE011 | Pfizer | Phase 1/2 | 32 |
| MEK162 | Pfizer | Phase 2 | 35 |
| Encorafenib + Binimetinib + cemiplimab+fianlimab | Regeneron Pharmaceuticals | Phase 2 | 42 |
| Plixorafenib + Cobicistat 150 MG [Tybost] | Brain Biotech | Phase 1 | 26 |
| Dabrafenib + Trametinib + Hydroxychloroquine | Brain Biotech | Phase 1/2 | 26 |